TriSalus Life Sciences Management
Management criteria checks 1/4
TriSalus Life Sciences' CEO is Mary Szela, appointed in Jan 2018, has a tenure of 8.42 years. total yearly compensation is $4.82M, comprised of 12.5% salary and 87.5% bonuses, including company stock and options. directly owns 0.71% of the company’s shares, worth $1.38M. The average tenure of the management team and the board of directors is 3.3 years and 2.8 years respectively.
Key information
Mary Szela
Chief executive officer
US$4.8m
Total compensation
| CEO salary percentage | 12.46% |
| CEO tenure | 8.4yrs |
| CEO ownership | 0.7% |
| Management average tenure | 3.3yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
Long Term Embolization Trends And New Indications Will Reshape This Undervalued Medtech Story
Catalysts About TriSalus Life Sciences TriSalus Life Sciences develops and commercializes pressure enabled drug delivery technologies and catheters used in interventional procedures for solid tumors and other vascular conditions. What are the underlying business or industry changes driving this perspective?TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks
Summary TriSalus Life Sciences aims to achieve positive cash flow by 2025, driven by expanding sales of their TriNav system and reducing operating expenses. The PERIO-03 trial for nelitolimod, a potential treatment for liver-involved cancers, is a key catalyst, with top-line data expected later this year. Financially, TLSI reported a net loss of $30 million for FY 2024, but expects to be EBITDA positive with 50% sales growth in 2025. Despite risks like low cash reserves and potential dilution, I maintain a "buy" rating, contingent on continued sales growth and stable financial reporting. Read the full article on Seeking AlphaTriSalus Life Sciences: Falling Despite Moving Forward Into The Market
Summary TriSalus Life Sciences, Inc. is focusing on developing organ-targeted therapy delivery mechanisms and pairing them with their own drugs. Nelitolimod, a TLR9 activator, is showing promising results in various solid tumor contexts, including liver and pancreatic cancers. Despite financial concerns, TriSalus Life Sciences' growing sales and promising clinical data make them a potential bargain investment when considered for the longer term. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$57m |
| Dec 31 2025 | US$5m | US$601k | -US$70m |
| Sep 30 2025 | n/a | n/a | -US$71m |
| Jun 30 2025 | n/a | n/a | -US$33m |
| Mar 31 2025 | n/a | n/a | -US$30m |
| Dec 31 2024 | US$4m | US$601k | -US$33m |
| Sep 30 2024 | n/a | n/a | -US$59m |
| Jun 30 2024 | n/a | n/a | -US$58m |
| Mar 31 2024 | n/a | n/a | -US$68m |
| Dec 31 2023 | US$3m | US$518k | -US$64m |
| Sep 30 2023 | n/a | n/a | -US$53m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$51m |
| Dec 31 2022 | US$861k | US$464k | -US$50m |
Compensation vs Market: Mary's total compensation ($USD4.82M) is above average for companies of similar size in the US market ($USD1.59M).
Compensation vs Earnings: Mary's compensation has increased whilst the company is unprofitable.
CEO
Mary Szela (62 yo)
Ms. Mary T. Szela, M.B.A. B.S.N., serves as Independent Director at Averin Capital Acquisition Corp. since February 19, 2026. She is an Independent Director of Absci Corporation from July 7, 2025. She is D...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 8.4yrs | US$4.82m | 0.71% $ 1.4m | |
| Chief Financial Officer | less than a year | US$3.44m | 0.044% $ 85.9k | |
| Chief Commercial Officer | 1.4yrs | US$1.56m | 0.11% $ 212.2k | |
| Vice President of Marketing | no data | no data | no data | |
| Chief Regulatory | 5.3yrs | US$652.03k | 0.13% $ 246.8k | |
| Chief of Research | 6yrs | no data | 0.20% $ 395.6k | |
| Medical Director | 1.4yrs | no data | no data |
Experienced Management: TLSI's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 8.4yrs | US$4.82m | 0.71% $ 1.4m | |
| Independent Director | 5.4yrs | US$116.25k | 1.36% $ 2.7m | |
| Independent Director | 2.8yrs | US$128.75k | 2.07% $ 4.0m | |
| Independent Chairman | 9.6yrs | US$138.75k | 2.48% $ 4.8m | |
| Independent Director | less than a year | no data | 2.6% $ 5.1m | |
| Independent Director | 1.4yrs | US$240.71k | 0.050% $ 96.9k | |
| Independent Director | 1.4yrs | US$220.09k | 0.032% $ 62.9k |
Experienced Board: TLSI's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/04 22:58 |
| End of Day Share Price | 2026/06/04 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TriSalus Life Sciences, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Justin Walsh | JonesTrading Institutional Services, LLC |
| Frank Takkinen | Lake Street Capital Markets, LLC |